Lanean...
Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 o...
Gorde:
| Argitaratua izan da: | BMJ Case Rep |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMJ Publishing Group
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970267/ https://ncbi.nlm.nih.gov/pubmed/33727289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-239621 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|